Status:
COMPLETED
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Lead Sponsor:
Shire
Conditions:
Essential Thrombocythemia (ET)
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate how effective and safe SPD422 (Anagrelide Hydrochloride) is in Japanese subjects, diagnosed with Essential Thrombocythemia, who's previously treatment has e...
Eligibility Criteria
Inclusion
- Subjects must have previously been treated with a cytoreductive therapy and been intolerant or refractory to that therapy.
Exclusion
- Subjects should not have any other underlying conditions or medications that would confound the study analysis or interact with the study medication.
Key Trial Info
Start Date :
October 27 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 24 2012
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT01214915
Start Date
October 27 2010
End Date
October 24 2012
Last Update
June 9 2021
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Akita University Hospital
Akita, Akita, Japan, 05 010-8543
2
Juntendo University Hospital
Hongo 3-1-3, Bunkyo-ku, Japan, 13 113-8431
3
Tokyo Metropolitan Cancer and Infectious diseases Center Kom
Honkomagome 3-18-22, Bunkyo-ku, Japan, 13 113-8677
4
Nippon Medical School Hospital
Sendagi 1-1-5, Bunkyo-ku, Japan, 13 113-8603